Cambridge Newswire

Comprehensive Real-Time News Feed for Cambridge, MA.

Results 1 - 20 of 40 for "" in Cambridge, MA

  1. Momentum for Climate Deal Grows as Obama Joins Xi in ParisRead the original story

    3 hrs ago | The Washington Post

    More than 140 world leaders including U.S. President Barack Obama and Xi Jinping of China are gathering in Paris for France's biggest diplomatic event since 1948, striving to reach the first truly global deal to curb greenhouse gases. The two weeks of United Nations-sponsored talks have already gathered pledges to reduce emissions from 177 of the 195 countries involved, signaling broader support for a deal than when envoys last attempted to reach one six years ago.


  2. Would You Pay $19 for a Ticket Out of Airport Hell?Read the original story w/Photo

    Thursday Nov 19 | The Washington Post

    A startup called Freebird will buy you a new seat when the airline gods are angry, no questions asked. But there's a catch-mostly for them.


  3. Ex-Biogen R&D Head Williams Thinks Small With Codiak VentureRead the original story

    Tuesday Nov 17 | The Washington Post

    Doug Williams, the former head of research at Biogen Inc., believes that good things come in small packages. After four years at the biotech giant, he's moving to a far smaller company to investigate a technology based on tiny containers discharged by cells.


  4. Delta Turns to Partitions for Feel of - Premium Economy' in CoachRead the original story w/Photo

    Monday Nov 16 | Bloomberg

    Delta Air Lines Inc.'s quest to add a dash of luxury and exclusivity to its priciest economy seats will mean erecting some walls. Once the U.S. government approves, Delta will install partitions to separate its extra-legroom "Comfort+" section from the rest of the main cabin on domestic jets, spokesman Anthony Black said Monday.


  5. Biogen to Fire Workers, Restructure R&D After Difficult YearRead the original story

    Oct 21, 2015 | The Washington Post

    The company said the cuts to its workforce of about 8,000 people will save about $250 million a year. It comes after several periods of disappointing results and a stock price that is down 22 percent this year.


  6. Biogen Under Turnaround Pressure Months After Hitting RecordRead the original story

    Oct 14, 2015 | The Washington Post

    The biotech giant has plummeted 46 percent from that high point, leaving shares down 25 percent this year, compared with a 1.6 percent decline for the Nasdaq Biotechnology Index. Shares closed at $256.04 on Tuesday, the lowest since November 2013.


  7. Biogen Under Turnaround Pressure Months After Hitting a RecordRead the original story

    Oct 14, 2015 | The Washington Post

    Seven months ago, Biogen Inc. shares were soaring to a record as investors flocked to biotech stocks and were tantalized by the prospects of the company's experimental drug for Alzheimer's disease. The biotech giant has plummeted 46 percent from that high point, leaving shares down 25 percent this year, compared with a 1.6 percent decline for the Nasdaq Biotechnology Index.


  8. Princeton University's Deaton Wins 2015 Nobel Prize in EconomicsRead the original story

    Oct 12, 2015 | Bloomberg

    Angus Deaton of Princeton University was awarded the 2015 Nobel Prize in Economics for his detailed analysis and measurement of consumer spending and global poverty. "To design economic policy that promotes welfare and reduces poverty, we must first understand individual consumption choices," the Royal Swedish Academy of Sciences said on Monday, in announcing the award.


  9. Yellen's Bell-Bottoms Era Plan Has Critics Singing the BluesRead the original story

    Oct 7, 2015 | Bloomberg

    Janet Yellen is pursuing a monetary policy with echoes from an era of bell-bottom jeans and New York Knicks' basketball championships. And that's got some economists worried.


  10. OvaScience's Chief Executive Dipp Sees Pay Tumble With SharesRead the original story

    Oct 2, 2015 | The Washington Post

    Michelle Dipp, chief executive officer of fertility-treatment maker OvaScience Inc., has watched her compensation plummet 85 percent so far this year amid a decline in her company's shares. The value of Dipp's package fell to $4.31 million from $28.2 million awarded at the end of 2014, according to the Bloomberg Pay Index.


  11. Early Promise for a New Paralysis TreatmentRead the original story w/Photo

    Oct 1, 2015 | Bloomberg

    Four months ago, Roger, a 55-year-old construction worker from Mooresville, N.C., fell out of a deer stand and was left with a damaged spinal cord and no sensation from the middle of his chest down. Patients with his condition typically have less than a 1-in-20 chance of recovering any feeling in or control over the paralyzed areas.


  12. Harvard, MIT Research Reaps $55 Million for Cancer StartupRead the original story

    Oct 1, 2015 | The Washington Post

    Boston-based Third Rock Ventures led the financing, which was the second-largest series A funding round in the world this year, according to data compiled by PitchBook Data Inc. Israeli health-care investment firm Clal Biotechnology Industries Ltd. and its parent company, Access Industries, run by billionaire Len Blavatnik, also contributed financing. Scientists involved in the creation of the company include Eric Lander, founding director of the Broad Institute, the genetic research organization run by Harvard and MIT, and researchers at the Harvard-affiliated Dana-Farber Cancer Institute and the Houston-based MD Anderson Cancer Center.


  13. Robert E. Simon Jr., Reston, Virginia's Founder, Dies at 101Read the original story w/Photo

    Sep 21, 2015 | Bloomberg

    Robert E. Simon Jr., whose planned community of Reston, Virginia, became home to almost 60,000 people in the suburbs of Washington, has died. He was 101.


  14. Alnylam Drug May Challenge Sanofi, Regeneron, AmgenRead the original story

    Sep 1, 2015 | The Washington Post

    The experimental drug belongs to a group of treatments that target a protein, PCSK9, that lets too much bad cholesterol circulate in the blood. The results were presented Sunday at the European Society of Cardiology Congress in London.


  15. Alnylam's New Drug May Be Threat to Sanofi, Regeneron, AmgenRead the original story

    Aug 31, 2015 | The Washington Post

    A drug from Alnylam Pharmaceuticals Inc. and Medicines Co. cut bad cholesterol levels among patients in a small trial by about as much as new treatments from Sanofi, Regeneron Pharmaceuticals Inc. and Amgen Inc., with far less frequent dosing.


  16. Here's One Thing Standing Between You and Cheaper GasolineRead the original story

    Aug 28, 2015 | The Washington Post

    And there's at least one thing standing in the way of a steeper decline at the pumps: ethanol. While the crude rout dragged gasoline futures down about 60 cents a gallon, ethanol's dropped a mere 15 cents -- making it costlier than gasoline this week for the first time since January.


  17. Biogen, Columbia to Map ALS Disease Genes With Ice Bucket MoneyRead the original story

    Aug 18, 2015 | The Washington Post

    Biogen Inc. and Columbia University Medical Center will map the genes and clinical traits of 1,500 people with ALS, also known as Lou Gehrig's disease, in an attempt to find a treatment for the devastating neurodegenerative disorder. The effort is being financed in part out of the $115 million the ALS Association raised last year in a viral fundraising campaign that had people dump buckets of ice water over their heads and challenge others to do the same.


  18. Gates, Google Join $120 Million Funding for Genome Editing FirmRead the original story

    Aug 10, 2015 | Bloomberg

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Editas Medicine Inc. has raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fatal genetic diseases.


  19. Drug Projected at $1 Million Has Spark Mulling Installment PlanRead the original story

    Aug 6, 2015 | The Washington Post

    Drugmaker Spark Therapeutics Inc. is considering installment payments for a promising gene therapy for blindness that analysts are projecting will come with a hefty price tag. The company is in discussions with health insurers and drug benefits managers about staggered-payment alternatives including pay-for-performance models that would spread costs over an extended period based on effectiveness, Chief Executive Officer Jeff Marrazzo said in an interview.


  20. In Race to Treat Rare Disease, Sarepta Seeks PurchasesRead the original story

    Jul 16, 2015 | The Washington Post

    The two companies are in a race to bring the products to market, and buying a drug could let Sarepta eventually combine therapies into a more effective cocktail. BioMarin submitted its drug to the U.S. Food and Drug Administration in April, beating Cambridge, Massachusetts-based Sarepta by a matter of weeks.


Cambridge Job Listings
View or post Cambridge job listings on Topix.
Cambridge Real Estate
News, listings, and foreclosures in Cambridge from Topix.
Cambridge Mortgages
Find mortgage rates in Cambridge on Topix.